PAP
CUE icon

Persistent Asset Partners’s Cue Biopharma CUE Stock Holding History

Persistent Asset Partners’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.67K Buy
+1,112
New +$10.4K ﹤0.01% 290

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $1.84B AUM 19.34% 1-Year Est. Return

Persistent Asset Partners's CUE Position: Q1 2026 in Review

Persistent Asset Partners opened a new position in Cue Biopharma (CUE) in Q1 2026: 1,112 shares worth $7.67K. The stake represents ﹤0.01% of the portfolio and ranks #290 among its holdings.

55 funds tracked by Wall St. Rank hold CUE as of Q1 2026.

  • Persistent Asset Partners held 1,112 shares of Cue Biopharma worth $7.67K as of Q1 2026.
  • Cue Biopharma was a new Persistent Asset Partners position in Q1 2026.
  • Cue Biopharma made up ﹤0.01% of Persistent Asset Partners's portfolio in Q1 2026, its #290 holding.
  • 55 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.